BeyondSpring Company
BeyondSpring is a global, clinical-stage biopharmaceutical company. Developing Innovative Immuno-Oncology Cancer Therapies with a Robust Pipeline from Internal Development and from Collaboration with University of Washington in De Novo Drug Discovery Using a Ubiquitination Platform.
BeyondSpring’s BPI-002 is a small molecule agent indicated for treating various infections including COVID-19. It has the ability to activate CD4+ helper T cells and CD8+ cytotoxic T cells and generating an immune response in the body. If combined with another COVID-19 vaccine, the drug has the ability to generate long-term protection against viral infections. BeyondSpring has filed US patent protection for the drug for treating viral infections.
BeyondSpring’s BPI-002 is a small molecule agent indicated for treating various infections including COVID-19. It has the ability to activate CD4+ helper T cells and CD8+ cytotoxic T cells and generating an immune response in the body. If combined with another COVID-19 vaccine, the drug has the ability to generate long-term protection against viral infections. BeyondSpring has filed US patent protection for the drug for treating viral infections.
Technology:
COVID
Industry:
Vaccine/Drug
Headquarters:
United States
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership